Abstract
The hemagglutinin (HA) of some influenza viruses can bind MHC-II, but how these proteins interact is unclear. Here we demonstrate that diverse H5 HAs can use avian or human MHC-II to enter cells. We define the molecular interface by using pseudovirus deep mutational scanning to measure how mutations to both H5 HA and an avian MHC-II affect the interaction between the two proteins. We leverage identification of mutations to HA and MHC-II that increase their binding to each other to determine a 3.4-angstrom cryo-EM structure of the complex. The structure shows that HA binds to MHC-II using a surface on the globular head distinct from the sialic acid receptor-binding pocket. The recognition surface on MHC-II consists of a portion of the alpha chain near the peptide-binding groove. We further show that H7 HA interacts with MHC-II similarly to H5 HA, and that H1, H2, and H9 HAs also bind avian or human MHC-II.
Competing Interest Statement
J.D.B. and B.D. are inventors on Fred Hutch licensed patents related to the pseudovirus deep mutational scanning and a provisional patent on MHC-II binding deficient HA vaccine antigens. J.D.B consults for Apriori Bio, GSK, Merck, and Pfizer. J.D.B. holds stock options in the Vaccine Company. N.P.K. is a paid consultant of AstraZeneca.
Funder Information Declared
National Institute of Allergy and Infectious Diseases, 75N93021C00015, U19AI181881
National Cancer Institute, P30CA015704
Washington Research Foundation, https://ror.org/00hasdx88, postdoctoral fellowship to Sara Sunshine
Howard Hughes Medical Institute, https://ror.org/006w34k90
Source: BioRxIV, https://doi.org/10.64898/2026.07.17.738765
____

No comments:
Post a Comment